Payment overview · 2025
General Payments
$15.21
1 reported records · 1 companies
Healthcare provider profile · identity verified
John A Kruba, DO
Allopathic & Osteopathic Physicians|Family Medicine · PALM SPRINGS, CA · NPI 1922092923
Verified facts
What the public records show
CMS Open Payments records show John A Kruba, DO received $15.21 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.21 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $15.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 146 |
| Lisinopril | Lisinopril | 384 | 110 |
| Gabapentin | Gabapentin | 331 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 92 |
| Omeprazole | Omeprazole | 311 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 308 | 90 |
| Losartan Potassium | Losartan Potassium | 307 | 90 |
| Trazodone Hcl | Trazodone Hcl | 284 | 73 |
| Montelukast Sodium | Montelukast Sodium | 273 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 252 | 50 |
| Metformin Hcl | Metformin Hcl | 242 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 78 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 234 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 69 |
| Baclofen | Baclofen | 205 | 67 |
| Alprazolam | Alprazolam | 172 | 39 |
| Carvedilol | Carvedilol | 167 | 47 |
| Lorazepam | Lorazepam | 161 | 39 |
| Temazepam | Temazepam | 158 | 42 |
| Simvastatin | Simvastatin | 157 | 48 |
| Descovy | Emtricitabine/Tenofov Alafenam | 147 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 35 |
| Furosemide | Furosemide | 143 | 54 |
| Finasteride | Finasteride | 131 | 43 |
| Tramadol Hcl | Tramadol Hcl | 126 | 33 |
| Eliquis | Apixaban | 125 | 28 |
| Famotidine | Famotidine | 123 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 33 |
| Alendronate Sodium | Alendronate Sodium | 118 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 25 |
| Atenolol | Atenolol | 103 | 35 |
| Ibuprofen | Ibuprofen | 102 | 33 |
| Acyclovir | Acyclovir | 97 | 33 |
| Potassium Chloride | Potassium Chloride | 96 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 89 | 22 |
| Diazepam | Diazepam | 88 | 21 |
| Verapamil Er | Verapamil Hcl | 86 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 30 |
| Testosterone | Testosterone | 81 | 25 |
| Allopurinol | Allopurinol | 78 | 24 |
| Tivicay | Dolutegravir Sodium | 76 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 75 | 24 |
| Meloxicam | Meloxicam | 74 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 21 |
| Valacyclovir | Valacyclovir Hcl | 68 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 16 |
| Bupropion Xl | Bupropion Hcl | 64 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | 18 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 60 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 19 |
| Azithromycin | Azithromycin | 59 | 46 |
| Benazepril Hcl | Benazepril Hcl | 58 | 15 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 16 |
| Prezcobix | Darunavir/Cobicistat | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 18 |
| Celecoxib | Celecoxib | 51 | 17 |
| Pregabalin | Pregabalin | 51 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 12 |
| Prednisone | Prednisone | 50 | 41 |
| Glimepiride | Glimepiride | 49 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 16 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 48 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 14 |
| Jardiance | Empagliflozin | 45 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 23 |
| Azelastine Hcl | Azelastine Hcl | 43 | 22 |
| Ezetimibe | Ezetimibe | 43 | 11 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | 13 |
| Valsartan | Valsartan | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Ozempic | Semaglutide | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 15 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 40 | suppressed |
| Primidone | Primidone | 40 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 14 |
| Spironolactone | Spironolactone | 37 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 17 |
| Lactulose | Lactulose | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | 14 |
| Estradiol | Estradiol | 31 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 18 |
| Ketoconazole | Ketoconazole | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Tadalafil | Tadalafil | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 11 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nevirapine Er | Nevirapine | 23 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 19 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | 11 |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Alprazolam Xr | Alprazolam | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.21 · 1 records | ABBVIE INC. | BOTOX, QULIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error